173 related articles for article (PubMed ID: 28831147)
21. A structure-function perspective of Jak2 mutations and implications for alternate drug design strategies: the road not taken.
Gnanasambandan K; Sayeski PP
Curr Med Chem; 2011; 18(30):4659-73. PubMed ID: 21864276
[TBL] [Abstract][Full Text] [Related]
22. JAK2 inhibitors: not the next imatinib but researchers see other possibilities.
Garber K
J Natl Cancer Inst; 2009 Jul; 101(14):980-2. PubMed ID: 19584324
[No Abstract] [Full Text] [Related]
23. The discovery of 2,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 2 (JAK2) inhibitors versus JAK1 and JAK3.
Lee SM; Yoon KB; Lee HJ; Kim J; Chung YK; Cho WJ; Mukai C; Choi S; Kang KW; Han SY; Ko H; Kim YC
Bioorg Med Chem; 2016 Nov; 24(21):5036-5046. PubMed ID: 27555284
[TBL] [Abstract][Full Text] [Related]
24. ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation.
Hammarén HM; Ungureanu D; Grisouard J; Skoda RC; Hubbard SR; Silvennoinen O
Proc Natl Acad Sci U S A; 2015 Apr; 112(15):4642-7. PubMed ID: 25825724
[TBL] [Abstract][Full Text] [Related]
25. Roles of germline JAK2 activation mutation JAK2 V625F in the pathology of myeloproliferative neoplasms.
Wu QY; Ma MM; Fu L; Zhu YY; Liu Y; Cao J; Zhou P; Li ZY; Zeng LY; Li F; Wang XY; Xu KL
Int J Biol Macromol; 2018 Sep; 116():1064-1073. PubMed ID: 29782975
[TBL] [Abstract][Full Text] [Related]
26. Critical role of FANCC in JAK2 V617F mutant-induced resistance to DNA cross-linking drugs.
Ueda F; Sumi K; Tago K; Kasahara T; Funakoshi-Tago M
Cell Signal; 2013 Nov; 25(11):2115-24. PubMed ID: 23838005
[TBL] [Abstract][Full Text] [Related]
27. [Research advances in the role of JAK2 mutations in acute leukemia].
Zhang HY; Zhai XW
Zhongguo Dang Dai Er Ke Za Zhi; 2015 Jun; 17(6):644-9. PubMed ID: 26108332
[TBL] [Abstract][Full Text] [Related]
28. Ab initio modeling and experimental assessment of Janus Kinase 2 (JAK2) kinase-pseudokinase complex structure.
Wan X; Ma Y; McClendon CL; Huang LJ; Huang N
PLoS Comput Biol; 2013 Apr; 9(4):e1003022. PubMed ID: 23592968
[TBL] [Abstract][Full Text] [Related]
29. Disruption of R867 and Y613 interaction plays key roles in JAK2 R867Q mutation caused acute leukemia.
Wu QY; Ma MM; Zhang S; Cao J; Yan ZL; Chen C; Li ZY; Zeng LY; Wang XY; Li F; Xu KL
Int J Biol Macromol; 2019 Sep; 136():209-219. PubMed ID: 31199972
[TBL] [Abstract][Full Text] [Related]
30. Disruption of E627 and R683 interaction is responsible for B-cell acute lymphoblastic leukemia caused by JAK2 R683G(S) mutations.
Wu QY; Guo HY; Li F; Li ZY; Zeng LY; Xu KL
Leuk Lymphoma; 2013 Dec; 54(12):2693-700. PubMed ID: 23452118
[TBL] [Abstract][Full Text] [Related]
31. Mechanisms of constitutive activation of Janus kinase 2-V617F revealed at the atomic level through molecular dynamics simulations.
Lee TS; Ma W; Zhang X; Giles F; Kantarjian H; Albitar M
Cancer; 2009 Apr; 115(8):1692-700. PubMed ID: 19195039
[TBL] [Abstract][Full Text] [Related]
32. Roles of T875N somatic mutation in the activity, structural stability of JAK2 and the transformation of OCI-AML3 cells.
Chen C; Li F; Ma MM; Zhang S; Liu Y; Yan ZL; Chen W; Cao J; Zeng LY; Wang XY; Xu KL; Wu QY
Int J Biol Macromol; 2019 Sep; 137():1030-1040. PubMed ID: 31299252
[TBL] [Abstract][Full Text] [Related]
33. JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias.
Kim SK; Knight DA; Jones LR; Vervoort S; Ng AP; Seymour JF; Bradner JE; Waibel M; Kats L; Johnstone RW
Genes Dev; 2018 Jun; 32(11-12):849-864. PubMed ID: 29907650
[TBL] [Abstract][Full Text] [Related]
34. Regulation of JAK2 activation by Janus homology 2: evidence from molecular dynamics simulations.
Wan S; Coveney PV
J Chem Inf Model; 2012 Nov; 52(11):2992-3000. PubMed ID: 23033920
[TBL] [Abstract][Full Text] [Related]
35. Pharmacophore and docking-based virtual screening approach for the design of new dual inhibitors of Janus kinase 1 and Janus kinase 2.
Jasuja H; Chadha N; Kaur M; Silakari O
SAR QSAR Environ Res; 2014; 25(8):617-36. PubMed ID: 25148044
[TBL] [Abstract][Full Text] [Related]
36. Design, synthesis and evaluation of pyrrolo[2,3-d]pyrimidine-phenylamide hybrids as potent Janus kinase 2 inhibitors.
Wang T; Liu X; Hao M; Qiao J; Ju C; Xue L; Zhang C
Bioorg Med Chem Lett; 2016 Jun; 26(12):2936-2941. PubMed ID: 27130359
[TBL] [Abstract][Full Text] [Related]
37. Loss of Tyrosine Kinase 2 Does Not Affect the Severity of
Yamaji T; Shide K; Kameda T; Sekine M; Kamiunten A; Hidaka T; Kubuki Y; Shimoda H; Abe H; Miike T; Iwakiri H; Tahara Y; Sueta M; Yamamoto S; Hasuike S; Nagata K; Shimoda K
Anticancer Res; 2017 Jul; 37(7):3841-3847. PubMed ID: 28668884
[TBL] [Abstract][Full Text] [Related]
38. The saga of JAK2 mutations and translocations in hematologic disorders: pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms.
Smith CA; Fan G
Hum Pathol; 2008 Jun; 39(6):795-810. PubMed ID: 18538168
[TBL] [Abstract][Full Text] [Related]
39. Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia.
Malinge S; Ben-Abdelali R; Settegrana C; Radford-Weiss I; Debre M; Beldjord K; Macintyre EA; Villeval JL; Vainchenker W; Berger R; Bernard OA; Delabesse E; Penard-Lacronique V
Blood; 2007 Mar; 109(5):2202-4. PubMed ID: 17068151
[TBL] [Abstract][Full Text] [Related]
40. Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?
Tibes R; Mesa RA
Leuk Lymphoma; 2011 Jul; 52(7):1178-87. PubMed ID: 21599574
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
